Shattuck Labs, Inc. (NASDAQ:STTK) Director Buys $166,713.75 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) Director Redmile Group, Llc purchased 133,371 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of $1.25 per share, with a total value of $166,713.75. Following the acquisition, the director now directly owns 5,539,724 shares in the company, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shattuck Labs Price Performance

Shares of NASDAQ STTK traded down $0.06 on Friday, hitting $1.25. The company's stock had a trading volume of 422,146 shares, compared to its average volume of 448,415. The stock has a 50 day moving average of $1.36 and a 200-day moving average of $3.42. The company has a market capitalization of $59.68 million, a price-to-earnings ratio of -0.84 and a beta of 1.76. Shattuck Labs, Inc. has a 12-month low of $0.94 and a 12-month high of $11.76.

Wall Street Analyst Weigh In

STTK has been the topic of several recent analyst reports. HC Wainwright restated a "neutral" rating on shares of Shattuck Labs in a research report on Friday, November 15th. Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Citigroup downgraded Shattuck Labs from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Finally, Evercore ISI raised Shattuck Labs to a "strong-buy" rating in a report on Wednesday, October 2nd. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $8.67.

Institutional Investors Weigh In On Shattuck Labs

A number of large investors have recently bought and sold shares of STTK. Vanguard Group Inc. boosted its stake in shares of Shattuck Labs by 38.2% during the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company's stock valued at $16,270,000 after acquiring an additional 502,860 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company's stock worth $857,000 after buying an additional 150,340 shares in the last quarter. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 15.0% in the second quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company's stock valued at $2,314,000 after buying an additional 78,177 shares during the last quarter. Ritholtz Wealth Management lifted its stake in shares of Shattuck Labs by 57.4% during the second quarter. Ritholtz Wealth Management now owns 142,540 shares of the company's stock valued at $550,000 after buying an additional 52,000 shares during the period. Finally, Rhumbline Advisers acquired a new stake in Shattuck Labs during the second quarter worth approximately $182,000. Institutional investors and hedge funds own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.